<scp>IL</scp>‐33 attenuates EAE by suppressing <scp>IL</scp>‐17 and <scp>IFN</scp>‐γ production and inducing alternatively activated macrophages
Hui‐Rong Jiang(University of Strathclyde), Foo Y. Liew(University of Glasgow), Wanda Niedbała(University of Glasgow), Anne‐Galle Besnard(University of Glasgow), Marija Milovanović(University of Kragujevac), Christopher Linington(Centre for Immunity, Infection and Evolution), José C. Alves‐Filho(University of Glasgow), Sandra Yasuyo Fukada(Universidade de Ribeirão Preto), Miodrag L. Lukić(University of Kragujevac), Dieudonnée Togbe(Université d'Orléans), Damo Xu(Shenzhen University), Carl S. Goodyear(University of Glasgow), Debbie Allan(University of Strathclyde)
Cited by 304
Related Papers
Myelin-oligodendrocyte glycoprotein antibody-associated disease
|The Lancet Neurology|2021|518
IL-1 family nomenclature
|Nature Immunology|2010|341
Interleukin‐33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells
|International Journal of Cancer|2013|326
Concise Review: Mesenchymal Stem Cell Treatment of the Complications of Diabetes Mellitus
|Stem Cells|2010|286
IL-33/ST2 axis in inflammation and immunopathology
|Immunologic Research|2012|259